Pulse Biosciences reports 86% met thyroid nodule reduction target in six-month interim study results
PLSE•Pulse Biosciences reported that 86% of 43 patients with benign thyroid nodules met the reduction target in six-month interim results from the PRECISE-BTN study of its nPulse Vybrance device.
1. Interim study results
Pulse Biosciences reported six-month interim PRECISE-BTN results for its nPulse Vybrance device in 43 patients with benign thyroid nodules. The company said 86% met the thyroid nodule reduction target, with improvements in symptoms and quality of life; no serious adverse events were reported.
